Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Aura Biosciences, Inc.NASDAQ: AURA
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $102K (cash outflow) fell 45.5% year over year, ahead of the -73.2% change in trailing-twelve-month capital expenditures. Sequentially, it fell 42.0% from the prior quarter. Over 3 fiscal years it compounded at -25.8% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -45.5% holds above the trailing-twelve-month pace of -73.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (447K) USD
- Year-over-year change
- +64.3%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (447K) | +64.3% |
| FY2024 | 2024-12-31 | (1.25M) | -76.7% |
| FY2023 | 2023-12-31 | (709K) | +35.2% |
| FY2022 | 2022-12-31 | (1.09M) | +48.5% |
| FY2021 | 2021-12-31 | (2.13M) | — |
Capital Expenditures vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -73.2% is the 6th highest of 9, against a peer median of -52.2%.
- Over three fiscal years its annual growth of -25.8% compares with a peer median of -19.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $9.67M USD | +36.9% | +239.3% | — | |
| FY2025 | $9.58M USD | +234.9% | +60.8% | 147.5% | |
| LTM Mar 2026 | $4M USD | +27.7% | +15.1% | 52.5% | |
| LTM Mar 2026 | $1.73M USD | -37.7% | -19.2% | 1.1% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $552K USD | -66.6% | +7.5% | 7.7% |
| LTM Mar 2026 | $362K USD | -73.2% | -25.8% | — | |
| LTM Mar 2026 | CHF 294.17K CHF | -77.9% | -56.7% | 58.4% | |
| LTM Mar 2026 | $175K USD | -83.3% | -65.4% | 3.9% | |
| LTM Mar 2026 | $106.68K USD | -94.2% | -50.1% | 0.2% | |
| LTM Mar 2026 | $13K USD | — | -19.6% | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding AURA) | — | -52.2% | -19.2% | 5.8% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.25M) | (58.76M) | (76.41M) | (86.92M) | (106.19M) |
| Depreciation & Amortization | 831K | 1.18M | 1.3M | 1.22M | 1.13M |
| Deferred Income Tax | 14K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.31M | 6.41M | 8.77M | 11.72M | 14.32M |
| Change in Working Capital | (315K) | (3.1M) | 4.44M | (2.64M) | 5.97M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.05M | 340K | (1.04M) | 482K | (846K) |
| Other Working Capital | (1.37M) | (3.44M) | 5.48M | (3.12M) | 6.82M |
| Other Non-Cash Items | 4K | (325K) | (1.95M) | (3.19M) | 32K |
| Operating Cash Flow | (32.41M) | (54.6M) | (63.85M) | (79.81M) | (84.74M) |
| Capital Expenditures | (2.13M) | (1.09M) | (709K) | (1.25M) | (447K) |
| Acquisitions (Net) | 0 | 66.78K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (119.78M) | (233.65M) | (59.11M) | (83.96M) |
| Sales of Investments | 0 | 53.01M | 120.4M | 129.18M | 120M |
| Other Investing Activities | 0 | (66.78K) | 0 | 0 | 0 |
| Investing Cash Flow | (2.13M) | (67.87M) | (113.96M) | 68.82M | 35.6M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 78.7M | 8.55M | 3.17M | 1.6M | 77.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 334K | 430K | 1.5M | 0 | 0 |
| Financing Cash Flow | 166.26M | 95.63M | 97.29M | 1.6M | 77.16M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (186K) |
| Net Change in Cash | 131.72M | (26.84M) | (80.52M) | (9.39M) | 27.82M |
| Free Cash Flow | (34.54M) | (55.7M) | (64.56M) | (81.06M) | (85.19M) |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.